UF-led researchers link new genetic mutation to increased risk of Parkinson’s
New research by a University of Florida-led international team has revealed evidence linking a new genetic mutation to greater risk of developing Parkinson’s disease.
New research by a University of Florida-led international team has revealed evidence linking a new genetic mutation to greater risk of developing Parkinson’s disease.
Under the leadership of Drs. Matthew Burns and Sub Subramony, the Fixel Institute receives recognition as an Ataxia Center of Excellence by the National Ataxia Foundation.
Check in with the National Ataxia Foundation library of resources ranging from medication, to exercise, to caregiver resources and more.
SKYCLARYS was tested and approved by the FDA to treat Friedrich’s ataxia.
Under the direction of Dr. Nikolaus McFarland, the Fixel Institute receives renewal as a Huntington’s Disease Society of America (HDSA) Center of Excellence.
Researchers discover using icepacks on the arms and hands may reduce or stop tremors caused by tacrolimus, a medication used for immune system suppression after organ transplant surgery.
University of Florida neurogeneticist Matthew Farrer contributed to the new Michael J. Fox Foundation Global Genetic PD Cohort.
In a recent study, researchers at the Norman Fixel Institute for Neurological Diseases at UF Health and the University of Florida College of Pharmacy used Medicare data to compare the rate of hospitalizations and deaths between two common Parkinson’s disease medications: pimavanserin and quetiapine.
UF neuroscientists provide preclinical evidence for adoptive cellular therapy as a potential immunotherapy treatment to improve symptoms in genetic form of Parkinson’s.
A recent Parkinson’s Foundation study estimates that nearly 90,000 people in the U.S. are diagnosed with Parkinson’s disease each year.